STOCKHOLM — Current treatments for age-related macular degeneration (AMD) have proven effective and safe. However, these lifelong therapies involve frequent ocular injections. "It can be ...

Recently published Wet AMD Market Insights report includes a comprehensive understanding of current treatment practices, wet ...

In their closing thoughts, the expert panelists discuss the future of the disease state and treatment options, and how they expect provider, patient, and payer value perception to change in the future ...

Age-related macular degeneration (AMD) is a leading cause of vision loss among people aged 50 and older. While treatments for the wet form of AMD have shown promise, the dry form, which accounts for ...

Please provide your email address to receive an email when new articles are posted on . Bispecifics are a relatively new area in ophthalmology. In 2022, faricimab was the first-ever FDA-approved ...

Armed with a recent authorization from the FDA, eye specialists are offering light therapy to patients with non-exudative (dry) age-related macular degeneration (AMD), aiming to stop or even reverse ...

Outlook Therapeutics, Inc. has announced a key development in the treatment of wet age-related macular degeneration (wet AMD) with the National Institute for Health and Care Excellence (NICE) ...

Please provide your email address to receive an email when new articles are posted on . Adjusted Cox model showed that each additional year of acetylcholinesterase inhibitor treatment was linked with ...

Share on Pinterest Researchers compared two drugs for treatment of wet age-related macular degeneration. Emilija Manevska/Getty Images About 170 million people globally live with age-related macular ...

Dr Sheth discusses the evolution of access to treatment for AMD/DME over the past few years and initiatives to expand treatment access. Jim Kenney, RPh, MBA: Dr Sheth, can you describe generically how ...